Kranten1 l.r..jpg

N E W S 

17 November 2021

Dutch stem cell biotech Neuroplast secures € 10 million (US$ 11.5 million) in Series B funding to further advance its transformative stem cell therapy for Traumatic Spinal Cord Injury.

Read more

09 November 2021

Dutch stem cell biotech Neuroplast announces successful clinical Phase I trial with its Neuro-Cells® stem cell treatment for Traumatic Spinal Cord Injury.

Read more

 

21 October 2021

Dutch stem cell biotech Neuroplast appoints TiGenix founder Frank Luyten and Sanquin director Pieter
de Geus to its supervisory board.

Read more

 

19 November 2020

Neuro-Cells® in patient. Neuroplast BV announced the first patient with chronic spinal cord injury was treated with Neuro-Cells®.

Read more
 

18 February 2020

Neuroplast raises € 4 million for its stem cell-based technology to treat patients with Spinal Cord Injury. 

Read more

01 May 2019

European Medicines Agency (EMA) has granted Orphan Drug Designation to Neuroplast treatment. 

Read more